Congo residents hope for Ebola cure as experimental treatments begin

Key Points:

• Researchers have launched a study in Bunia, Congo, testing two experimental treatments—remdesivir and antibody treatment MBP134—aimed at improving survival rates for patients infected with the Bundibugyo strain of Ebola, which currently has no specific treatments or vaccines.
• The World Health Organization (WHO) and international partners are conducting the trial, with survival tracked for 28 days post-treatment; the study initially focuses on confirmed patients in treatment centers, with plans to include high-risk individuals like healthcare workers in a second phase.
• The outbreak has resulted in over 1,400 diagnosed cases and 438 deaths, with significant challenges including community mistrust, overcrowded treatment centers, delayed care-seeking, and insecurity limiting access to affected areas.
• Local residents express cautious hope that the experimental treatments could bring relief and help control the outbreak, though some remain skeptical about the safety and fairness of the research.
• Due to ongoing violence and security concerns in the region, the trial is currently limited to Bunia’s Evangelical Medical Centre, with plans to expand to other locations as conditions permit.